4CPS-098 Use of palivizumab in the immunoprofilaxis of respiratory syncytial virus

BACKGROUND: Palivizumab is a monoclonal antibody that provides passive immunity against respiratory syncytial virus (RSV). PURPOSE: To evaluate the use of palivizumab as immunoprophylaxis against RSV in the 2016 to 2017 campaign in a tertiary hospital. MATERIAL AND METHODS: Retrospective observation...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Hosp Pharm
Main Authors: Marín, M, Alzueta, N, Molins, E, Pio, M, Gascon, A
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.189
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki